Abstract
Purpose of review:
The review provides updates on novel risk markers for the development of pediatric inflammatory uveitis and a severe disease course, on treatment of refractory disease, and on the measurement of visual outcomes.
Recent findings:
There are several new genetic markers, biomarkers, and clinical factors that may influence a child's uveitis disease course. It is important to identify children at risk for poor visual outcomes and who are refractory to traditional therapy. Racial disparities have recently been reported. We describe agents of potential benefit. In addition, we discuss the importance of patient reported outcomes in this population.
Summary:
Uveitis can lead to vision-threatening complications. Timely and aggressive treatment of children identified to be at risk for a severe uveitis course may lead to improved outcomes.
MeSH terms
-
Adolescent
-
Adrenal Cortex Hormones / therapeutic use*
-
Antirheumatic Agents / therapeutic use*
-
Aqueous Humor / chemistry
-
Arthritis, Juvenile / epidemiology
-
Autoimmune Diseases / drug therapy*
-
Autoimmune Diseases / epidemiology
-
Autoimmune Diseases / genetics
-
Autoimmune Diseases / immunology
-
Black or African American
-
Blood Sedimentation
-
Child
-
HLA-B27 Antigen / genetics
-
HLA-DR1 Antigen / genetics
-
HLA-DRB1 Chains / genetics
-
Humans
-
Methotrexate / therapeutic use
-
Recurrence
-
Risk Factors
-
S100 Proteins / immunology
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Uveitis / drug therapy*
-
Uveitis / epidemiology
-
Uveitis / genetics
-
Uveitis / immunology
-
Visual Acuity
Substances
-
Adrenal Cortex Hormones
-
Antirheumatic Agents
-
HLA-B27 Antigen
-
HLA-DR1 Antigen
-
HLA-DRB1 Chains
-
S100 Proteins
-
Tumor Necrosis Factor-alpha
-
Methotrexate